Does Kaiser Medicare Cover Wegovy? Medicare Advantage Coverage Guide 2026
Medicare Advantage enrollees on Kaiser Senior Advantage (from Kaiser Permanente) frequently want to know whether Kaiser Medicare covers Wegovy (semaglutide 2.4mg). Here’s the overview: coverage is determined by your plan’s formulary tier, Part D structure, and medical indication.
Kaiser Medicare’s Formulary Position on Wegovy
Kaiser Senior Advantage maintains a drug formulary that classifies medications by patient cost. As of 2026, Wegovy is usually classified as Tier 4 (Non-preferred specialty) for typical Kaiser Medicare plan variants.
Cost implications:
- Out-of-pocket cost: $100–$300+ based on plan variant and drug tier
- Prior authorization: Mandatory — your doctor must submit
- Quantity limits: May apply — limited to FDA-recommended dosing
- Step therapy: Might need failed trial of metformin, insulin, or other treatments first
The Medicare Part D coverage gap (donut hole), cost-sharing increases to a larger share until reaching the catastrophic threshold.
Coverage for Different Indications
For chronic weight management (FDA-approved):
- Kaiser Medicare is more likely to cover Wegovy when prescribed for its FDA-approved indication
- Required evidence: lab work and prescription history
- Coverage is more consistent when used on-label
For weight loss (if seeking obesity coverage):
- Original Medicare Part D excludes anti-obesity medications for weight loss alone
- However: 2025 policy changes broadened Part D coverage eligibility for GLP-1s prescribed for obesity
- Kaiser Medicare might include additional drug benefits that include weight management medications — check your Evidence of Coverage document
What You’ll Pay With Kaiser Medicare
Understanding your out-of-pocket cost for Wegovy on Kaiser Medicare requires knowing which Part D coverage phase you’re in.
| Coverage Phase | Estimated Cost |
|---|---|
| Initial Deductible ($545 in 2026) | Full retail price: $1,300–$1,500/month |
| Initial Coverage | $100–$300/month |
| Coverage Gap (Donut Hole) | ~$250–$350/month |
| Catastrophic Coverage | Minimal cost |
Starting in 2025, out-of-pocket Part D spending is capped at $2,000/year — which significantly helps patients on expensive specialty drugs.
Navigating the PA Process
- Request a formulary exception — If Wegovy is non-preferred, your doctor can file for a coverage exception with supporting documentation
- Use Novo Nordisk’s savings programs — Novo Nordisk runs savings programs for eligible Medicare enrollees (note: savings cards typically don’t work with government plans)
- Compare plans during open enrollment — Annual Enrollment Period (Oct 15–Dec 7) lets you switch to a plan with better Wegovy coverage
- Explore LIS — For qualifying individuals can qualify for LIS benefits that slash out-of-pocket expenses